GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through the GeneDx segment. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. It provides carrier/variant-specific testing, targeted mosaic variant testing, and others.
Unternehmens-codeWGS
Name des UnternehmensGeneDx Holdings Corp
IPO-datumSep 04, 2020
Gegründet am2020
CEOMs. Katherine A. Stueland
Anzahl der mitarbeiter1000
WertpapierartOrdinary Share
GeschäftsjahresendeSep 04
Addresse333 Ludlow Street
StadtSTAMFORD
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl06902
Telefon18887291206
Websitehttps://sema4.com/
Unternehmens-codeWGS
IPO-datumSep 04, 2020
Gegründet am2020
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten